Chemistry:Ezobresib
From HandWiki
Ezobresib is an investigational new drug that has been evaluated for the treatment of cancer. It inhibits Bromodomain and Extra-Terminal domain (BET) proteins, with potential antineoplastic activity.[1] Developed by Bristol Myers Squibb, this therapeutic agent has been studied for its efficacy in treating various cancers, including solid tumors and hematological malignancies.[2] Despite showing promise in early-phase clinical trials, recent developments suggest that Bristol Myers Squibb has decided to discontinue further development of ezobresib.[3]
References
- ↑ "An updated patent review of BRD4 degraders". Expert Opinion on Therapeutic Patents 34 (10): 929–951. October 2024. doi:10.1080/13543776.2024.2400166. PMID 39219068.
- ↑ "Clinical Trials Using Ezobresib". National Cancer Institute. https://www.cancer.gov/research/participate/clinical-trials/intervention/ezobresib.
- ↑ "Bristol backs out of BET inhibition". ApexOnco. https://www.oncologypipeline.com/apexonco/bristol-backs-out-bet-inhibition.
 |  |
